Carmat elects heart industry veterans to board
This article was originally published in Clinica
Carmat, a Velizy, France-based start-up developing a fully-implantable artificial heart for late-stage heart failure patients, has expanded its board of directors with three new members. They are: André-Michel Ballester, CEO of Italian cardiovascular device company Sorin; Peter Steinmann, former vice-president of Medtronic, and Michel Finance, acting CEO of Carmat. This brings the total number of board directors to six. The other members include chairman Jean-Claude Cadudal, founder and chief scientific officer Professor Alain Carpentier, and general partner of Truffle Capital, Dr Philippe Pouletty.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.